INTRODUCTION
Engineered nanoparticle platforms have been developed intensely in recent years, yielding significantly broadened applications from interrogating novel biology to new therapies. The mammalian immune system has emerged as perhaps the most powerful physiological system where nanoparticle design parameters have drastic implications for nanoparticle fate and function. In particular, the innate immune system is a major concern due to its role as the firstline defense against foreign invaders, responsible for initiating and maintaining the innate immune response as well as priming the adaptive immune response. Understanding how nanoparticles are perceived from a biological perspective is crucial to informing their design with different immunogenic, immunosuppressive, or stealth properties. Nanoparticles are particularly susceptible to innate immune responses such as opsonization and recognition by receptors that enable phagocytic uptake or evoke strong inflammatory responses due to the recognition of various "danger" signals. In this review, we will summarize some of the key advances in our understanding of how physical and biochemical parameters of nanoparticles interact with innate immunity, and note potential opportunities and emerging frontiers for controlling and evaluating nanoparticle-immune interactions.
One of the most basic parts of the innate immune system that is at once incredibly simplistic and highly complicated and organized is the complement system. The complement system is often one of the first responders to pathogens. Complement involves a unique set of proteins that transform through a cascade of reactions from inactive to active forms, ultimately leading to clearance of pathogens. There are three pathways to the complement system: the classical, lectin, and alternative pathways. In the classical pathway, C1q, one of the three subunits of the first component of complement, binds to antibody-antigen complexes and initiates the cascade. In the lectin pathway, mannose binding lectin binds to sugars on pathogens.
In the alternative pathway, activation can be spontaneous due to adsorption of complement on pathogen or materials surfaces. Not surprisingly, materials introduced into the body tend to activate the complement system by the alternative pathway due to adsorption and binding to surfaces. The complement cascade involves activation, amplification, progression, and regulation. An excellent review of the complement system is in Zipfle and Skerka 1 . Complement activation can happen quite rapidly. Following injury, changes in complement factor have been documented to occur over hours and can continue for days 2, 3 . Very few papers look at changes in critical players in the complement cascade over time periods of less than an hour, but for infusible nanomedicines, this time period may be critical.
To facilitate clearance, opsonization enhances the activity of innate immune cells including phagocytosis (uptake) and activation of effector functions. Innate immune cells include a diverse set of circulating and tissue-resident cells that include granulocytes (neutrophils, basophils, eosinophils, mast cells) and antigen-presenting cells (APCs) such as monocytes, macrophages, and dendritic cells. Uptake duties are performed by both neutrophils and APCs; particles that are phagocytosed are degraded and interrogated by the ingesting cell. Interrogation is achieved by a diverse array of receptors that can directly facilitate pathogen recognition, uptake, and generate an immune response. These receptors and mechanisms include pattern classical pattern recognition receptors (such as Toll-like receptors (TLRs) and C-type lectin receptors (CLRs)) as well as emerging pathways such as inflammasomes and autophagy, and the different receptors can be expressed on either cell membranes (TLRs, CLRs) or in the cytosol (NOD-like receptors, NLRs; RIG-I-like receptors (RLRs) (reviewed extensively in 4 ). Each family member binds specific molecular patterns often referred to as danger signals, consisting of molecules with structures and/or subcellular localization that are different from the host and often conserved among foreign microbes. Examples include TLR4 recognition of extracellular bacterial lipopolysaccharide, NLR/inflammasome recognition of cytosolic bacterial DNA or peptidoglycan, and RLR recognition of cytosolic viral RNA. A major endpoint for these pathways is the activation of effector functions, including the secretion of inflammatory cytokines, chemokines, histamine, and various other molecules as well as the activation of cellular processes such as apoptosis. It is notable that all of these receptors typically recognize microbes or other particulates in the low micrometer to sub-micron size range, so it is unsurprising that engineered nanoparticles are subject to surveillance and interrogation by these pathways. It is becoming increasingly clear that the host response to nanoparticles, particularly host tolerance of nanoparticle therapies and therapeutic efficacy, are dependent upon their interactions with the innate immune system.
CLINICALLY RELEVANT INNATE IMMUNE MECHANISMS FOR NANOMEDICINES
One of the most well-known nanomedicines is DOXIL for cancer therapy. DOXIL is a liposomal formulation of doxorubicin. It must be infused at a very slow rate compared to other chemotherapy agents to avoid a complement-mediated response; DOXIL is infused at a rate of 1 mg/ml over the course of hours compared to a bolus over 3-10 minutes for doxorubicin. Even with this slow infusion rate, approximately 10% of patients have a response that leads to serious cardiac side effects during the first administrations that can be dose limiting 5 . It should be noted that with repeated administrations, the patient response is lessened.
DOXIL is far from the only nanomedicine with a complement-associated infusion reaction. Some iron oxide formulations for MRI contrast have been withdrawn from the clinic for complement activation issues 6 . Furthermore, complement-associated reactions are seen in a small number of patients who get intravenous nanoparticle iron infusions for severe anemia.
A diverse range of nanomaterials from intravenously infused poly(lactic-co-glycolic acid) In a similar vein, nanoemulsions are oil-in-water systems stabilized by surfactants and are currently the only approved adjuvants for use in human vaccines. Their mechanisms of action remained undetermined for decades, but recent studies have begun to identify key components of that trigger innate immunity. In particular, inflammasomes appear to be critically important.
Inflammasomes are a relatively new arm of innate immunity that are responsible for driving acute inflammation during infection, and can cause autoimmune disorders if unchecked. Notably, crystals such as silica, aluminum salt, or monosodium urate (cause of gout), are known to activate inflammasome cascades, increasing their immunogenicity via inflammatory cytokines as well as prostaglandin E2 (antibody-promoting) from macrophages [9] [10] [11] [12] [13] . The over-arching mechanism has been suggested to be lysosomal disruption, such that any internalized material causing this effect (even in a "sterile" context) would be sufficient to activate the NLRP3 inflammasome 11 . Consistent with this, another study indicated that small silver nanoparticles (30-1000 nm diameter) effectively induced lysosomal destabilization and inflammasome activation in macrophages 14 . Macrophage NLRP3 is also activated by titania and silica nanoparticles 15 . Intriguingly, this study also demonstrated that nanoparticle-mediated activation of inflammasomes may be independent of uptake, a paradigm that is distinct from the hypothesis of lysosomal disruption and seems to circumvent the dogma indicating uptake is required for immune recognition and signaling of particulates. Regardless, it is abundantly clear that nanomedicines have significant clinical implications that depend upon interactions with innate immunity.
COMPLEMENT AND COMPLICATIONS
The big question is what are the implications for activating the complement cascade with intravenously delivered nanomedicines. Administration of nanomedicines that activate the complement system, cleaving C3 to C3a, can trigger degranulation of cells including endothelial and mast cells leading to allergic-like responses. This can cause a host of responses termed complement-activation related pseudoallergy (CARPA) [16] [17] [18] . CARPA is a hypersensitivity reaction that can be life threatening. The symptoms of CARPA include: increase in heart rate, hypotension, flushing of the skin (erythema), decreased cardiac output, decreased pulmonary pressures, and decreased blood gas levels [16] [17] [18] . Not every person will have a life-threatening response, but based on the DOXIL data, approximately 10% of patients will have a serious enough response to require halting administration 5 . Genetic differences are known to contribute to the complement response to nanomedicines, but it is not currently possible to predict a patient's response to an intravenous infusion of a nanomaterial 19 .
Cytokine storms are another major concern in nanoparticle toxicity, and may be driven both by endotoxin contamination of nanoparticle preparations 20 as well as uncontrolled activation of various cells of the innate immune system by the biomaterial itself. Cytokine storms, similar to CARPA, are life-threatening, acute events that can occur during organ transplant, infection or infusion of therapeutics 21, 22 . Symptoms of cytokine storm are shared with CARPA such as edema, erythema, fever, and hypotension. Additionally, organ and local tissue pathological damage occurs due to altered perfusion, intense local inflammation or fibrosis. Multiple organ failure can be the result of high systemic levels of cytokines and recruitment of immune cells, and organ dysfunction can persist in non-fatal cases 22 . An increasing array of nanomedicines are entering clinical trials and even receiving FDA approval (e.g., the recent breakthrough approval of MM-398, a nanoliposomal formulation of irinotecan), so the clinical impact of immune responses to on-market nanomaterials (partially summarized in Table 1 ) presents an important issue for preclinical and clinical investigation. . The infusion rate is critical to the CARPA response, and as discussed with DOXIL, slower infusions can reduce the response significantly. The CARPA response is also reduced with repeated administrations 24 .
To that end, if infusion of a nanomedicine is anticipated, an empty carrier can be infused to help ameliorate the hypersensitivity reaction before the delivery of the nanomedicine 27 . This approach may alleviate CARPA, and potentially other innate immune pathways by inducing tolerance or exhaustion (such as endotoxin tolerance 28 ).
Even with all of these measures, some patients still have significant reactions that limit treatment. Furthermore, for some therapies, such as intravenously administered hemostatic agents [29] [30] [31] [32] [33] [34] , the methods to limit CARPA responses would not be possible. If one administers a hemostatic agent too slowly in response to an injury, bleed out may occur before the nanomaterial is present in sufficient quantities to be effective. 
CRITICAL FEATURES OF BIOMATERIALS FOR INNATE IMMUNE RECOGNITION
If one cannot administer a nanomedicine in a way avoids the hypersensitivity reaction of CARPA, can one engineer the nanomaterials to reduce complement activation? Potentially, yes.
The molecular features on nanomedicines matter: surface charge, corona molecules, size, and shape of the nanomaterials have all been shown to matter for complement activation [35] [36] [37] .
While groups have begun to investigate features of nanoparticles that impact immune activation 36 , there has been no systematic study that provides clear guidelines to direct the design of the 
Size
Size matters in a multitude of ways. As the particle size increases, the surface area per mass decreases. Particles greater in size than a few microns show significantly reduced complement activation 39 . Size is often considered at the tissue physiology level when studying trafficking and systemic distribution. However, size also has a significant impact on direct cellular interactions of biomaterials with the immune system. The role of size is vastly different at the macroscale (>100 μm) and microscale (>1 μm) compared to the nanoscale (1-1000 nm), with the foreign body response dominating objects larger than the nanoscale. A notable recent study demonstrated that extremely large spherical implants (>1. nanoparticles. Gold nanoparticles had significant effects on macrophages compared to silver nanoparticles of similar size, potentially due to increased uptake/retention of gold nanoparticles.
Toxicity was found to be size-dependent, with small gold nanoparticles more toxic than larger ones. Importantly, cytotoxicity can shape of immune responses via triggering distinct types of cell death that can be more or less immunogenic 44 . A conflicting study demonstrated that gold nanoparticles alone did not induce cytokines from macrophages, and that small ~4 nm gold nanoparticles actually inhibited TLR9 signaling significantly compared to large ~45 nm gold 
Surface properties and modification
Not surprisingly, the surface molecules on nanomaterials, particularly those that are water soluble, play an important role in complement activation. Surface modification of poly(lactic-coglycolic acid) nanoparticles with glucosamine has been shown to reduce complement activation 53 . Dextrans can reduce complement activation at high surface coverage where there is limited ability for C3 to adsorb 54 . A similar effect is seen with high PEGylation, and the density and organization of PEG matters. Brush conformation for PEG is critical to avoid activating complement and this requires PEG of specific molecular weight and density on the surface of the particle 55 . Another way to think about this is that PEGylation for stealth may require very specific tuning to achieve the optimal effect of increased half-life with minimal immunotoxicity, particularly with repeated doses of PEGylated nanoparticles 56 . This is at least partially due to anti-PEG antibodies. Anti-PEG antibodies are even reported to develop in response to empty ~100 nm PEGylated liposomes, suggesting an inherent immunogenicity of PEG that may accelerate or promote opsonization and complement activation upon repeated dosing 57, 58 . It is quite possible that with higher densities of PEG promoting brush conformation that these antibodies to PEG may be slower to form, but this hypothesis remains to be tested. shown to activate inflammatory responses in macrophages, and these were abrogated by TLR4 inhibition 64 . In contrast to those studies, gold nanoparticles were shown to provoke no inherent immune response in macrophages; instead, they directly bound lysosomal HMGB1 and inhibited TLR9 signaling 65 . .
Receptor-based recognition of components, charge
In addition to lipids, polymers can also be recognized by a variety of immune cells.
Polymeric carrier subunits can be haptenated (a process where small molecules complex with carriers to create an immunogen) to generate IgM antibodies by directly activating B cells 69 .
This study utilized fluorescein as a hapten and determined that commonly used polymers including Ficoll, dextran, cellulose, and polyvinyl alcohol could all be made immunogenic after haptens exceeded thresholds for molecular weight and valency. Polyanyhydride nanoparticles directly triggered TLR-2, -4, and -5 to promote Th1 responses in DCs 70 . Interestingly, this study showed that pre-immunization with empty nanoparticles protected mice against a lethal Salmonella challenge, suggesting increased CD8+ T cell responsiveness caused by nanoparticles alone. In fact, diverse TLRs (TLR-4, in addition to TLR2 and -6) can be engaged by polymers on DCs 71 , suggesting a potential universal recognition mechanism for polymers. Cumulative evidence above and structural information on the nature of TLR recognition indicate that the exposed hydrophobic regions of polymers or adsorbed proteins may be a main driver of these interactions. Hydrophobicity is hypothesized to serve as a conserved type of danger signal that may be detected as either abnormally folded/exposed protein regions or in various nanoparticle materials 72 .
By further determining what receptors can directly recognize biomaterials, and the molecular and biophysical determinants of recognition, there remain abundant opportunities to tune either biomaterial composition or properties to avoid recognition or to actively monitor and suppress receptor recognition or immune response during nanoparticle administration.
The charge on the surface of a nanoparticle has a significant effect on complement activation. Negatively-charged liposomes increase complement activation and CARPA in vivo 17 .
More negative charge increases both hemolysis and complement activation on a range of particles in vitro [35] [36] [37] . Increasing hydroxylation of surfaces on more negatively charged particles increases complement activation in vitro suggesting, based on the work looking at the role of hydroxyls on surfaces 52 , that complement activation may be due, at least in part, to the presence of hydroxyl molecules that can covalently bind to C3b 25 . As summarized in Table 2 , critical features of nanomaterials that are found to dictate innate immune interactions include size, surface molecule coating, and net charge, and these properties all interact with immunity via diverse pathways that are context-dependent in vitro and in vivo. APCs induced the expression of the tolerogenic molecule PD-L1. These results indicate that the gut nanomineral pathway may be a homeostatic mechanism for tuning gut innate immunity.
Given the tolerogenic fate of this pathway, targeting nanoparticles to the gut using nanominerals may provide a new immune silent pathway for stealth nanoparticle uptake and systemic delivery after oral or gastrointestinal delivery. Determining the biochemical and physical properties required to take advantage of this pathway should be a focus of future work to fully utilize the tolerogenic transcytosis of the gut.
Another emerging strategy for creating stealth materials uses biomimetic or bio-derived coatings. Red blood cell (RBC) membrane-coated nanoparticles have been developed to reduce circulating alloantibody concentrations in in a model of hemolytic transfusion 75 . The protein CD47 has been identified as one crucial component of RBC membranes that results in increased circulation and decreased macrophage uptake compared to PEGylation 76, 77 . CD47-based self-stealthing has been further developed, including the identification of minimal peptides to inhibit phagocytosis 78 . In addition, other properties of RBC membranes are suggested to result in inherently neutral immune processing, with no detectable anti-RBC protein responses arising in a vaccine nanotoxin preparation 79 . Nanoparticles have also been coated with leukocyte membranes, yielding similar stealthing but enhanced receptor-ligand interactions 80 . Coating with cancer cell membranes yields antigen presentation for effective vaccination as well as homotypic cancer-cell fusion of coated nanoparticles in situ 81 . These developing techniques may greatly enhance our ability to stealth nanoparticles from the immune system and modulate their function, mitigating issues such as the emergence of anti-PEG immunity and targeting uptake/delivery.
What is critical at this point for understanding the relationship between molecular design and immune activation is taking all of this data and working through the specifics of features like surface charge and density of corona molecules to be able to go beyond saying something does or does not lead to immune activation to determine specific ranges for these values to direct the design of nanomedicines. Towards this goal, future work should focus on increasing our ability to screen and predict immunotoxicity of various nanomaterials in a variety of assays. Particularly useful would be prognostic signatures or biomarkers that would direct the design and choice of nanomaterials. Assuming that most nanomaterials activate complement via the alternative pathway, incubation with EGTA will not affect complement activation but EDTA will. The data regarding the ratio of C3 to C3a and C5a are complemented by measurements of SC5b-9 (terminal membrane attack complex) following incubation of serum with the nanomaterial. Ultimately, though, one would like to be able to look at the complement response not only in vitro but in vivo to correlate it with the in vitro findings particularly with regards to complications such as the CARPA response.
MODELS FOR ASSESSING IMMUNE ACTIVATION BY NANOMATERIALS
The CARPA response exists both in rats and pigs, but the response in rats is far reduced in intensity and only seen at high doses. Pigs, like people, exhibit the response at very modest doses of nanoparticles (0.1 mg/kg) 82 . Thus, there is great value in also looking at the porcine response to nanomaterials for changes in complement. The challenge is that there are far fewer
ELISAs that are sensitive to porcine complement. Thus, an alternative used regularly in the field is the complement hemolytic activity test (CH50 test) in which the incubated serum is added to antibody-sensitized sheep erythrocytes 82, 83 . It is not as sensitive as ELISAs but provides a welcome alternative to quantifying complement in vitro and in vivo in the porcine model.
Many other immunoassays could be used to assess immunotoxicity of nanoparticles 84 .
The development of high-throughput, multiplex panels for quantitation of bioanalytes (e.g., cytokines, chemokines, antibodies, other proteins and biomolecules) makes for an ideal diagnostic platform, both preclinically and clinically [85] [86] [87] [88] . Prior to administration of therapy, patients could be challenged with low doses of biomaterials to determine whether there is potential for a hyperactive immune response by measuring circulating protein levels. Other potential diagnostics could directly test the activity of immune cells in blood ex vivo or cultured with biomaterials using cytokine output and/or other functional outcomes (cell proliferation, upregulation of activation-associated genes or proteins) 89, 90 ; other alternatives could use a more traditional grading approach based on gross clinical symptoms 91 . Ultimately, these diagnostics before administration or at the time of reaction could help identify targets for intervention; as an example, IL-6 was successfully utilized to alleviate cytokine storm in a tumor immunotherapy clinical case 92 .
CONCLUSIONS
The clinical application of nanomedicines and biomaterials is expanding quickly. In concert, many studies have investigated potential complications for nanoparticles in clinical implementation, in particular their potential for immune recognition and immunotoxicity. While diverse mechanisms and pathways have been implicated in responding to nanoparticle properties and composition, relatively little has been definitively shown about the specific structural and biophysical designs that elicit various immune reactions; future studies need to more exhaustively determine the design parameters causing these interactions. A number of promising strategies are emerging, in particular bio-inspired and bio-mimetics, which may enable a more advanced approach for stealthing of nanomedicines than traditional approaches such as PEGylation. These new approaches will be complemented by and directly benefit from more advanced studies on how precise molecular and physical properties guide immune outcomes, and rational, precise ways these properties can be modulated to create immune stealth or neutral outcomes for novel therapies.
